Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$1.18B+199.99%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Diggory William Howitt
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 5,400
- Beta
- 0.26
- Country
- AU
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 9.21
Financials
Revenue
$1.18B+200.0%Net Income
$-14.40M-118.5%EBITDA
$136.50M+20.3%Free Cash Flow
$208.32M+600.0%EPS (diluted)
$-0.11-116.2%Shares Outstanding (diluted)
130.80M+14.6%Operating Expenses
$719.72MCash & Debt
$187.71MReturn of Capital
$156.93MDividend per Share
$0.47Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $2.35B | $147.30M | $1.13 |
| 2025 | $2.34B | $388.90M | $2.97 |
| 2024 | $2.24B | $356.80M | $2.72 |
| 2023 | $1.96B | $300.60M | $2.29 |
| 2022 | $1.64B | $289.10M | $2.20 |
| 2021 | $1.49B | $326.50M | $2.47 |
| 2020 | $1.35B | $-238.30M | $-2.00 |
| 2019 | $1.45B | $276.70M | $2.40 |
| 2018 | $1.35B | $245.80M | $2.13 |
| 2017 | $1.25B | $223.62M | $1.95 |
| 2016 | $1.13B | $188.92M | $1.66 |
| 2015 | $925.63M | $145.84M | $1.27 |
| 2014 | $804.94M | $93.71M | $0.82 |
| 2013 | $752.72M | $132.56M | $1.16 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CHEOY's reported EPS growth of -0.2% a year over 13 years.
- EPS in 5 years
- $1.11
- Implied price
- $60.19
- Return from $43.58
- 6.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $29.92 — -31.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 38 | 46 | 54 | 62 | 70 |
|---|---|---|---|---|---|
| -10.2% | -10.5% | -7.0% | -4.0% | -1.3% | 1.1% |
| -5.2% | -5.5% | -1.9% | 1.3% | 4.2% | 6.7% |
| -0.2% | -0.6% | 3.3% | 6.7% | 9.7% | 12.4% |
| 4.8% | 4.4% | 8.5% | 12.0% | 15.2% | 18.0% |
| 9.8% | 9.4% | 13.7% | 17.4% | 20.6% | 23.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
155+121.43%Social Signal Score
Mentions (3)
- Newsreuters.com·7d ago·Neutral
Cochlear to defend shareholder class action over 2026 profit forecast Australian hearing implant maker Cochlear said on Tuesday it has been served with a shareholder class action in the Supreme Court of Victoria over its fiscal 2026 underlying net profit forecast.
View source ↗ - Newsbusinesswire.com·7d ago·Positive
Cochlear Reaches More Than 1 Million Hours of Patient Experience Across Its Fully Implantable Hearing Technology Research Program SYDNEY--(BUSINESS WIRE)--Cochlear today announced the completion of recruitment for the worldwide pivotal trial program evaluating fully implantable hearing technology. Patients across Cochlear's fully implantable hearing system research programs have experienced more than 1 million hours with their device to date. This reflects the most comprehensive research program
View source ↗ - Newsseekingalpha.com·49d ago·Positive
Cochlear Limited (CHEOY) Q4 2026 Earnings Call Transcript Cochlear Limited (CHEOY) Q4 2026 Earnings Call Transcript
View source ↗
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.